Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Medical Care : celebrates 40th anniversary of Schweinfurt plant, company's largest for dialysis machines

share with twitter share with LinkedIn share with facebook
share via e-mail
07/19/2019 | 12:40pm EDT

Press Release

Fresenius Medical Care, the world's largest provider of dialysis services and products, celebrated today the 40th anniversary of the company's Schweinfurt, Germany plant. Joining employees and their family members for the festivities were numerous business and political representatives, including Schweinfurt Mayor Sebastian Remelé.

Schweinfurt is Fresenius Medical Care's largest development and manufacturing facility for dialysis machines and other medical technology devices. Over the past four decades more than 800,000 dialysis machines have been made at the site, where the company is now investing some €20 million in a new, 8,000-square-meter (86,000-square-foot) technology center. The Schweinfurt facility's workforce now numbers more than 1,200, with about a third of the employees involved in research and development.

'Schweinfurt is a huge success story - not just for Fresenius Medical Care, but even more so for our patients around the world,' said Rice Powell, CEO of Fresenius Medical Care. 'For 40 years now, we have been developing life-sustaining products here at the very highest level, and we're doing our best to continue writing new chapters in that success story. With the building of the new technology center, we are working to mesh development and production at this site even closer together, so that we can provide even better dialysis machines for our patients in the future.'

'I am very proud that Fresenius Medical Care is established in Schweinfurt and from here developed into the world market leader for dialysis machines,' said Mayor Remelé. 'These dialysis systems are used to treat several hundred thousand patients with chronic kidney failure. In the name of the city of Schweinfurt, and personally, I want to wish Fresenius Medical Care continued great success in this important field.'

The plant's history dates back to 1979 and the acquisition of a vacant factory building in a Schweinfurt industrial zone. There, under the business name MTS Medizin-Technische Systeme Schweinfurt GmbH, 40 employees began producing the first dialysis machine developed by Fresenius - the A2008C, which won the gold medal for technical innovation at the Leipzig Trade Fair that same year. By 1984, every second dialysis machine produced in Germany was 'Made in Schweinfurt.' The A2008C would go on to become the world's leading and best-selling dialysis machine, a position Fresenius Medical Care still holds following the introduction of the A2008C's successor models. Today, more than half of all dialysis machines sold worldwide are made by Fresenius Medical Care.

Dialysis machines, bloodline systems and dialyzers - the latter often dubbed 'artificial kidneys' because this is where the blood is cleaned - are the most important products for treating chronic kidney disease. During treatment, the dialysis machine pumps the patient's blood through bloodlines, monitors its circulation through the dialyzer, and adds anti-coagulants. Treatments are generally carried out three times weekly, taking between three and six hours each.

6008 Dialysis machines in Schweinfurt plant

Visualization of the new technology center

Historic picture from Schweinfurt plant

Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3.4 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,971 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 336,716 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the company provides related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.


FMC - Fresenius Medical Care AG & Co. KGaA published this content on 19 July 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 July 2019 16:39:09 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
08/13FRESENIUS6CPRF : SANJOSE will reform the dialysis zone of the Lozano Blesa Hospi..
08/12FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
08/08FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 40, Section ..
08/07FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
08/05FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
07/30FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 50 of the Wp..
07/30Bridgepoint tests appetite for $2.2 billion dialysis clinic firm Diaverum - s..
07/30Fresenius slides as weakness in dialysis unit offsets improved outlook
07/30FRESENIUS MEDICAL CARE : Trades Lower After 2Q Results
07/30FRESENIUS : Raises 2019 Sales Guidance After Solid 2Q
More news
Financials (USD)
Sales 2019 19 410 M
EBIT 2019 2 601 M
Net income 2019 1 304 M
Debt 2019 8 958 M
Yield 2019 1,95%
P/E ratio 2019 15,1x
P/E ratio 2020 12,9x
EV / Sales2019 1,50x
EV / Sales2020 1,38x
Capitalization 20 130 M
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 88,98  $
Last Close Price 65,43  $
Spread / Highest target 70,3%
Spread / Average Target 36,0%
Spread / Lowest Target -24,7%
EPS Revisions
Rice Powell Chief Executive Officer
Dieter Schenk Chairman-Supervisory Board
Michael Brosnan Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
William P. Johnston Member-Supervisory Board